Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.56

+2.8%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (7876)	2/17/2003 10:03:17 AM
From: Spekulatius	Read Replies (1) of 52153

<< In Bristol's case, the market credits it with only $3.30 in market cap for every R&D dollar it spends. The market is valuing Bristol's pipeline at 40% below the industry average.>> The question is not how much $ BMY pours into R&D, its they accomplish with this money. BMY's R&D productivity is subpar compared to virtually all pharma peers so a discount is well justified. The schizophrenia drug is licensed in, isn't it?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next